Protocolli GOIRC-sponsored in fase di attivazione o sottomissione

GOIRC-01-2022 HEROS (osservazionale)

HER2 aberrations in advanced NSCLC: an Observational, retrospective and prospective, multi-centric Study exploring HER2 alterations incidence and therapeutic management in Italy

Centro Coordinatore: Parma

GOIRC-02-2024 IMMUNOSTAR

Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial - GOIRC-02-2024

Centro Coordinatore: Reggio Emilia

GOIRC-03-2024 REMAIN (osservazionale)

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in radically resected EGFR-mutated NSCLC patients: REMAIN study

Centro Coordinatore: Parma

GOIRC-06-2024 PROBreast

Mobile App to enhance engagement and communication with metastatic breast cancer patients: a feasibility study. PROBreast-GOIRC-06-2024

Centro Coordinatore: Meldola